ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform

Neoplasia

Volumn 6, Issue 1, 2004, Pages 1-6

  Rhodes, Daniel R ^a   Yu, Jianjun ^a   Shanker, K ^b   Deshpande, Nandan ^b   Varambally, Radhika ^a   Ghosh, Debashis ^a   Barrette, Terrence ^a   Pandey, Akhilesh ^c   Chinnaiyan, Arul M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Institute of Bioinformatics   (India)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Gene expression; Microarray; ONCOMINE; Transcriptome

Indexed keywords

ABELSON KINASE; BIOLOGICAL MARKER; CELECOXIB; CYCLOOXYGENASE 2; DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMATINIB; PHOSPHOTRANSFERASE; PROSTASIN; TRANSCRIPTOME; TRASTUZUMAB; UNCLASSIFIED DRUG;

BIOINFORMATICS; CANCER; CANCER RESEARCH; CANCER THERAPY; DATA BASE; DNA MICROARRAY; DRUG DEVELOPMENT; GENE EXPRESSION; GENE TARGETING; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GENOMICS; INFORMATION PROCESSING; INFORMATION SYSTEM; INTEGRATED DATA MINING PLATFORM; INTERNET; MEMBRANE; ONCOMINE; PRIORITY JOURNAL; REVIEW;

EID: 1642377561     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1476-5586(04)80047-2     Document Type: Review

References (47)

1. Alizadeh AA, Eisen MB, Davis RE, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511.
2. Alon U, Barkai N, Notterman DA, Gish K, Ybarra S, Mack D, and Levine AJ (1999). Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci USA 96, 6745-6750.
3. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, et al. (2002). Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8, 816-824.
4. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, et al. (2001). Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98, 13790-13795.
5. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, et al. (2002). Gene expression patterns in human liver cancers. Mol Biol Cell 13, 1929-1939.
6. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, and Chinnaiyan AM (2001). Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822-826.
7. Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen JL, Marcussen N, Hamilton-Dutoit S, Wolf H, and Orntoff TF (2003). Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33, 90-96.
8. Frierson HF Jr., El-Naggar AK, Welsh JB, Sapinoso LM, Su AI, Cheng J, Saku T, Moskaluk CA, and Hampton GM (2002). Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am J Pathol 161, 1315-1323.
9. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengerbach M, van de Rijn M, Rosen GD, Perou CM, Whyte RI, Altman RB, Brown PO, Botstein D, and Petersen I (2001). Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 98, 13784-13789.
10. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, and Isaacs WB (2001). Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 61, 4683-4688.
11. Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, Dhir R, Finkelstein S, Michalopoulos G, and Becich M (2002). Gene expression analysis of prostate cancers. Mol Carcinog 33, 25-35.
12. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, and Milbrandt J (2001). Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 61, 5692-5696.
13. Notterman DA, Alon U, Sierk AJ, and Levine AJ (2001). Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 61, 3124-3130.
14. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, and Botstein D (2000). Molecular portraits of human breast tumours. Nature 406, 747-752.
15. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, and Golub TR (2002). Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415, 436-442.
16. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, Ladd C, Reich M, Latulippe E, Mesirov JP, Poggio T, Gerald W, Loda M, Lander ES, and Golub TR (2001). Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci USA 98, 15149-15154.
17. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, Misek DE, Wu R, Zhai W, Darrah DM, Reed H, Ellenson LH, Giordano TJ, Fearon ER, Hanash SM, and Cho KR (2002). Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62, 4722-4729.
18. Rickman DS, Bobek MP, Misek DE, Kuick R, Bliavas M, Kurnit DM, Taylor J, and Hanash SM (2001). Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 61, 6885-6891.
19. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, et al. (2002). The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346, 1937-1947.
20. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, and Sellers WR (2002). Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1, 203-209.
21. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, and Borresen-Dale AL (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98, 10869-10874.
22. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, and Friend SH (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536.
23. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA, and Hampton GM (2001). Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 98, 1176-1181.
24. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriquez J, Moskaluk CA, Frierson HF, Jr., and Hampton GM (2001). Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61, 5974-5978.
25. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kuchli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, and Brown P (2002). Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161, 1991-1996. Erratum in: Am J Pathol 2003; 163: 377.
26. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kuchli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, and Brown P (2002). Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161, 1991-1996. Erratum in: Am J Pathol 2003; 163: 377.
27. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, and Chinnaiyan AM (2002). Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287, 1662-1670.
28. Tanwar MK, Gilbert MR, and Holland EC (2002). Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 62, 4364-4368.
29. Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, and Cramer DW (2001). Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 93, 1458-1464.
30. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI, Chen Y, Ma ZC, Wu ZO, Ye SL, Liu YK, Tang ZY, and Wang XW (2003). Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 9, 416-423.
31. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML, Pieters R, Kersey JH, Sallan SE, Fletcher JA, Golub TR, Griffin JD, and Korsmeyer SJ (2003). Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3, 173-183.
32. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causten HC, Gaasterland T, Glennison P, Holstege FC, Kim IF, Markowitz V, Matese JC, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J, and Vingron M (2001). Minimum information about a microarray experiment (MIAME)-toward standards for microarray data Nat Genet 29, 365-371.
33. Perou CM (2001). Show me the data! Nat Genet 29, 373.
34. Storey J (2002). A direct approach to false discovery rates. R Stat Soc 64, 479-498.
35. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, and Norton L (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344, 783-792.
36. Fujimura M, Katsumata N, Tsuda H, Uchi N, Miyazaki H, Hidaka T, Sakai M, and Saito S (2002). HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. Jpn J Cancer Res 93, 1250-1257.
37. Zinner RG, Kim J, and Herbst RS (2002). Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer 37, 17-27.
38. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, and Sherlock G (2000). Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25, 25-29.
39. Chen X, Ji ZL, and Chen YZ (2002). TTD: Therapeutic Target Database. Nucleic Acids Res 30, 412-415.
40. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL, and Seibert K (2000). Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60, 5599-5602.
41. Gee J, Sabichi AL, and Grossman HB (2002). Chemoprevention of superficial bladder cancer. Crit Rev Oncol Hematol 43, 277-286.
42. Konner J and O'Reilly E (2002). Pancreatic cancer: epidemiology, genetics, and approaches to screening. Oncology (Huntington) 16, 1615-1622 (1631-1612; discussion 1632-1613, 1637-1618).
43. Gleevec approved for first-line treatment of CML (2003). FDA Consum 37, 5.
44. Pruitt KD and Maglott DR (2001). RefSeq and LocusLink: NCBI gene-centered resources. Nucleic Acids Res 29, 137-140.
45. Navarro JD, Niranjan V, Peri S, Jonnalagadda CK, and Pandey A (2003). From biological databases to platforms for biomedical discovery. Trends Biotechnol (in press).
46. Diehn M, Sherlock G, Binkley G, Jin H, Matese JC, Hernandez-Boussard T, Rees CA, Cherry JM, Botstein D, Brown PO, and Alizadeh AA (2003). SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Res 31, 219-223.
47. Kanehisa M and Goto S (2000). KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 28, 27-30.